PHAZAR

PHAZAR: A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5-azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN.

Recruitment

PHAZAR Graph Interventional Sep2018Figure 1: PHAZAR Interventional component actual and target recruitment

 

PHAZAR Graph Observational Sep2018Figure 2: PHAZAR Observational component actual and target recruitment

Site NamePrincipal InvestigatorNumber of patients recruited
Guy's Hospital, London Professor Claire Harrison 8
Beatson West of Scotland Cancer Centre, Glasgow Dr Mark Drummond 5
The Queen Elizabeth Hospital, Birmingham Dr Fiona Clark 4
University Hospital of Wales, Cardiff Dr Steven Knapper 4
Southamptom General Hospital Dr Srivinasan Narayanan 4
Nottingham City Hospital Dr Jenny Byrne 3
Addenbrooke's Hospital, Cambridge Dr Anna Godfrey 2
Churchill hospital, Oxford Professor Adam Mead 2
Hammersmith Hospital, London Dr Dragana Milojkovic 2
Christie Hospital, Manchester Dr Tim Somervaille 2
St James's University Hospital, Leeds Professor David Bowen 2
St Bartholomew's Hospital, London Professor Jamie Cavenagh 0
University College London Hospital Dr Mallika Sekhar 0

Change of Staff

If there is a change of staff working on the trial please print off and complete the relevant registration form below. Please also ensure that the Signature and Delegation Log is updated. 

Trial Documents

Links to the current protocol, Patient Information Sheet, Informed Consent Form are provided below. If there has been a recent amendment to the trial please ensure you have R&D approval before using these documents.

Other documents (e.g. Amendments, Case Report Form, Serious Adverse Event Form, Guidelines, GP Letter, Release of Medical Information Form etc) can be found by clicking on the other menu items below. If you cannot find what you are looking for please contact the PHAZAR Trial Office.

Protocol

Patient Documents

Version Control Lists

The version numbers and dates of all documents used for the trial are captured on a Version Control List. Links to the Version Control Lists used in this trial are below in reverse date order.

Amendments

Below is a link to a document which lists all of the substantial protocol amendments which have been made for this trial. The folders below contain the relevant amended documentation and approval letters. Please ensure that you have R&D approval (if applicable) before using the latest versions of these documents.

 Guidelines

 

Case Report Forms

Case Report Forms

Interventional

 Observational

Tools

Pharmacy

Pharmacy Documents

Pharmacy File Version Control Checklists

Publications

To date there are no publications available for this trial.

News and Events

None at present

Contact Details

Chief Investigator
Dr Mark Drummond
Consultant Haematologist and Honorary Senior Lecturer
Haematology, Beatson Oncology Centre
Haematology Laboratory
21 Shelley Road, Gartnavel Hospital
Glasgow, G12 0XL

Tel:      +44 (0) 141 301 7712
Fax:     +44 (0) 141 301 7718

PHAZAR Trial Office
Trial Coordinator:               Mirjana Sirovica                     
Trial Monitor:                      Davina Scott
Trial Management Team Leader:    Sonia Fox
Trial Statistician:                Iklaaq Ahmed

Cancer Research UK Clinical Trials Unit (CRCTU)
Centre for Clincal Haematology
Queen Elizabeth Hospital
Edgbaston
Birmingham
B15 2TH

Enquiries
Telephone: +44 (0)121 371 7866
Fax:             +44 (0)121 371 7874
Email:          Phazar@trials.bham.ac.uk

Trial Entry
Telephone: +44 (0)121 371 7866                        (9.00 am till 5.00 pm Monday to Friday)

Serious Adverse Event Reporting
Fax: +44 (0)121 371 7874                          Or                         0121 371 4398

Sponsor

University of Birmingham
Correspondence to:
Cancer Research UK Clinical Trials Unit (CRCTU)
Centre for Clincal Haematology
Queen Elizabeth Hospital
Edgbaston,
Birmingham B15 2TH